FAST-GROWING drug company Hikma Pharmaceuticals will be swapping auditors from incumbents Deloitte to Big Four rivals PwC.
Hikma, which entered the FTSE 100 earlier this year for the first time since being founded in 1978 by a Palestinian refugee – announced the changes following a formal tender process where the board approved the appointment of PwC. Subject to shareholder approval at its 2016 AGM, Deloitte will stand down and hand over the reins to the $1.8m (£1.2m) audit and $0.5m non-audit fee account.
The firm primarily makes and sells out-of-patent drugs and has recently created a division dedicated to medicines delivered intravenously or via a syringe.
Pat Butler, chairman of the audit committee, said: “On behalf of the board, I would like to thank Deloitte for their significant contribution to Hikma since listing in 2005 and before that as a private company.”
As the UK navigates its way through the Brexit process, it has become imperative for finance leaders to find ways to understand and manage their currency risks. So, how are UK finance directors managing their currency risks in the face of Brexit uncertainty?
British business leaders are not optimistic about the future, according to a new business survey
Senior finance appointments parachuted in as investigation finds Redcentric overstated profits by £20m
Prime minister May outlines tax incentives to boost high-tech business, and further corporation tax rate cuts, to the CBI